▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1327 by analyst upside · 2026-06-27
CRSP
CRISPR Therapeutics AG
Healthcare · Market Cap $5B · P/E 0x
ANALYST PRICE TARGET
+52.1%
implied upside to consensus target
Current Price $54.92
Consensus Target $83.52
Bull Target $291.0
Bear Target $44.0
Analysts Covering 21
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
9
Hold
7
Sell
1
52-Week Low $44.12
52-Week High $78.48
YTD Return +2.1%
FUNDAMENTALS
Market Cap $5B
P/E Ratio (TTM) N/A
Forward P/E -14.3x
EPS (TTM) $-6.28
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $4M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $44.12
52-Week High $78.48
Current Price $54.92
Bear Target $44.0
Bull Target $291.0
● Now $54.92 ● Target $83.52
TRADING DATA
Avg Volume 1.7M
YTD Return +2.1%
Analyst Count 21
Consensus Buy
Upside to Target +52.1%
Last Updated 2026-06-27

ANALYST SUMMARY

CRISPR Therapeutics AG (CRSP) is currently trading at $54.92 with a Wall Street consensus price target of $83.52, implying potential upside of 52.1% over the next 12 months. 21 analysts currently cover CRSP, with a consensus rating of Buy - 62% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $291.0, while the most cautious has a target of $44.0.

CRSP operates in the Healthcare sector with a market capitalisation of $5B. The stock is up 2.1% year-to-date and is currently trading near the lower end of its 52-week range of $44.12 – $78.48.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

GRFS +47.0%
Grifols, S.A.
$5B · P/E 10.6x · Buy
STVN +37.1%
Stevanato Group S.p.A.
$5B · P/E 30.8x · Buy
ACAD +25.0%
ACADIA Pharmaceuticals Inc.
$4B · P/E 11.5x · Buy
INDV +21.2%
Indivior Pharmaceuticals, Inc.
$5B · P/E 21.2x · Buy
MMSI +24.8%
Merit Medical Systems, Inc.
$4B · P/E 30.9x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CRSP, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Bernstein — Reiterated
Market Perform → Market Perform 2026-05-13 Building track record
Citigroup — Reiterated
Buy → Buy 2026-05-06 Building track record
Piper Sandler reit
Overweight → Overweight 2026-03-17 14% win rate (7 calls)
Chardan Capital — Reiterated
Buy → Buy 2026-02-17 33% win rate (6 calls)
TD Cowen — Reiterated
Hold → Hold 2026-02-13 Building track record
Evercore ISI Group — Reiterated
Outperform → Outperform 2026-02-13 Building track record
Needham — Reiterated
Buy → Buy 2026-02-13 20% win rate (5 calls)
Citizens — Reiterated
Market Outperform → Market Outperform 2026-01-30 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
38
out of 100
Coverage depth
24/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →